Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -323,800 | -163,972 | -707,421 | -555,588 | -310,482 |
| Depreciation Amortization | 4,384 | 2,242 | 20,919 | 17,612 | 11,949 |
| Income taxes - deferred | N/A | N/A | -1,639 | N/A | N/A |
| Accounts receivable | -17,586 | -2,508 | -12,068 | -2,973 | -8,902 |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | 52,416 | 41,260 |
| Other Working Capital | -31,205 | -38,364 | 61,874 | 38,387 | 16,221 |
| Other Operating Activity | 95,179 | 45,735 | 257,870 | 160,023 | 55,176 |
| Operating Cash Flow | $-273,028 | $-156,867 | $-380,465 | $-290,123 | $-194,778 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 241,916 | 140,289 | -79,754 | 74,731 | 92,026 |
| PPE Investments | -38,972 | -25,034 | -116,123 | -89,153 | -63,107 |
| Net Acquisitions | N/A | N/A | -75,025 | -75,391 | N/A |
| Sale Of Investment | 14,627 | N/A | 10,094 | N/A | 42,950 |
| Purchase Sale Intangibles | -2,500 | N/A | -30,000 | -30,000 | -30,000 |
| Other Investing Activity | -6,849 | -3,951 | -30,844 | -30,240 | -30,063 |
| Investing Cash Flow | $210,722 | $111,304 | $-291,652 | $-120,053 | $41,806 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 32,326 | -750 | 10,813 | 8,812 | 7,738 |
| Other Financing Activity | -28 | 28 | 490,395 | 490,514 | -289 |
| Financing Cash Flow | $32,298 | $-722 | $501,208 | $499,326 | $7,449 |
| Exchange Rate Effect | 75 | 211 | -1,075 | -2,427 | -1,346 |
| Beginning Cash Position | 137,601 | 137,601 | 309,585 | 309,585 | 309,585 |
| End Cash Position | 107,668 | 91,527 | 137,601 | 396,308 | 162,716 |
| Net Cash Flow | $-29,933 | $-46,074 | $-171,984 | $86,723 | $-146,869 |
| Free Cash Flow | |||||
| Operating Cash Flow | -273,028 | -156,867 | -380,465 | -290,123 | -194,778 |
| Capital Expenditure | -38,972 | -25,034 | -116,123 | -89,153 | -63,107 |
| Free Cash Flow | -312,000 | -181,901 | -496,588 | -379,276 | -257,885 |